Subtype
Uterine Neoplasm
CI-CAN-00004208Explore in graph →
Non-malignant925 active trials7 approved drugs44 evidence items
Loading cancer entity…
Subtype
CI-CAN-00004208Explore in graph →
Clinical trials
3,823 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07168200 | A Phase III Clinical Study of Adebrelimab Combined With Concurrent Chemoradiotherapy Versus Placebo Combined With Concurrent Chemoradiotherapy for the Treatment of Locally Advanced Cervical Cancer | recruiting | Phase 3 | 720 | Shanghai Shengdi Pharmaceutical Co., LtdINDUSTRY | 1 | Apr 15, 2026 | clinicaltrials |
| NCT07418749 | A Study of SHR-A2102 Versus Investigator's Choice of Chemotherapy in Patients With Platinum-based Chemotherapy and PD-(L)1 Inhibitor Treatment Failed Recurrent or Metastatic Cervical Cancer | recruiting | Phase 3 | 398 | Suzhou Suncadia Biopharmaceuticals Co., Ltd. |
| 1 |
| Apr 6, 2026 |
| clinicaltrials |
| NCT07319429 | Refining Fertility-sparing Treatment in Endometrial Carcinoma Based on Molecular Classification(FEMUS) | recruiting | Phase 2 / Phase 3 | 260 | Fudan UniversityOTHER | 1 | Mar 13, 2026 | clinicaltrials |
| NCT06513065 | Study to Evaluate the Non-inferiority of Low-dose HIPEC Versus High-dose HIPEC in the Treatment of PMP (HIPEC-PMP)(HIPEC-PMP) | recruiting | Phase 3 | 176 | University of SouthamptonOTHER | 1 | Feb 19, 2026 | clinicaltrials |
| NCT07164534 | A Clinical Trial to Assess the Effectiveness of NRF2 Activator (Oral Sodium-copper- Chlophyllin ) in Locally Advanced Cervical Cancer to Reduce Late Radiotherapy Toxicity.(CHOC-LATE) | not yet recruiting | Phase 3 | 316 | Tata Memorial HospitalOTHER_GOV | 0 | Feb 4, 2026 | clinicaltrials |
| NCT06671548 | Efficacy & Safety Study of Relugolix in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids | recruiting | Phase 3 | 120 | Qilu Pharmaceutical Co., Ltd.INDUSTRY | 1 | Feb 2, 2026 | clinicaltrials |
| NCT06712472 | Randomized Phase III Trial Testing Maintenance Olaparib Versus Observation After Adjuvant Chemoradiation for p53abn Endometrial Cancer(RAINBO-RED) | recruiting | Phase 3 | 554 | Gustave Roussy, Cancer Campus, Grand ParisOTHER | 1 | Jan 20, 2026 | clinicaltrials |
| NCT00565851 | Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian, Epithelial, Primary Peritoneal, or Fallopian Tube Cancer | active not recruiting | Phase 3 | 1,052 | National Cancer Institute (NCI)NIH | 3 | Dec 30, 2025 | clinicaltrials |
| NCT07298642 | Extended-field Proton Therapy for Cervical Cancer | recruiting | Phase 2 / Phase 3 | 44 | National Taiwan University HospitalOTHER | 1 | Dec 23, 2025 | clinicaltrials |
| NCT03422198 | Short Course Vaginal Cuff Brachytherapy in Treating Participants With Stage I-II Endometrial Cancer(SAVE) | recruiting | Phase 3 | 188 | University of UtahOTHER | 1 | Dec 12, 2025 | clinicaltrials |
| NCT05077215 | Efficacy and Safety of a Repurposed Drug Added to the Combination of Len Plus Pem in Advanced Endometrial Cancer | not yet recruiting | Phase 3 | 450 | Evergreen Therapeutics, Inc.INDUSTRY | 0 | Dec 8, 2025 | clinicaltrials |
| NCT05201547 | Endometrial Cancer Patientes MMR Deficient Comparing Chemotherapy vs Dostarlimab in First Line(DOMENICA) | active not recruiting | Phase 3 | 260 | ARCAGY/ GINECO GROUPOTHER | 10 | Dec 4, 2025 | clinicaltrials |
| NCT05770102 | DETERMINE Trial Treatment Arm 02: Atezolizumab in Adult, Paediatric and Teenage/Young Adult Patients With Cancers With High Tumour Mutational Burden (TMB) or Microsatellite Instability-high (MSI-high) or Proven Constitutional Mismatch Repair Deficiency (CMMRD) Disposition(DETERMINE) | recruiting | Phase 2 / Phase 3 | 30 | Cancer Research UKOTHER | 1 | Nov 24, 2025 | clinicaltrials |
| NCT04537156 | Efficacy, Immunogenicity and Safety Study of Recombinant Human Papillomavirus Vaccine(6,11,16,18,31,33,45,52,58 Type)(E.Coli) | active not recruiting | Phase 3 | 9,327 | Xiamen UniversityOTHER | 1 | Nov 21, 2025 | clinicaltrials |
| NCT04982237 | A Study of AK104 Plus Platinum-containing Chemotherapy±Bevacizumab as First-line Treatment for Persistent, Recurrent, or Metastatic Cervical Cancer | active not recruiting | Phase 3 | 445 | AkesoINDUSTRY | 1 | Nov 19, 2025 | clinicaltrials |
| NCT07230626 | SYS6002 vs Chemotherapy in Recurrent or Metastatic Cervical Cancer | not yet recruiting | Phase 3 | 412 | CSPC Megalith Biopharmaceutical Co.,Ltd.INDUSTRY | 0 | Nov 17, 2025 | clinicaltrials |
| NCT04111978 | MAintenance Therapy With Aromatase Inhibitor in Epithelial Ovarian Cancer (MATAO)(MATAO) | recruiting | Phase 3 | 540 | Swiss GO Trial GroupNETWORK | 3 | Sep 29, 2025 | clinicaltrials |
| NCT07177716 | Efficacy and Safety of LB1410 Plus Lenvatinib With or Without LB4330 in Advanced Recurrent/Metastatic Cervical Cancer | not yet recruiting | Phase 2 / Phase 3 | 120 | L & L Bio Co., Ltd., Ningbo, ChinaINDUSTRY | 1 | Sep 17, 2025 | clinicaltrials |
| NCT04906993 | Camrelizumab Combined With Famitinib Malate for Treatment of Recurrent/Metastatic Cervical Cancer | active not recruiting | Phase 3 | 443 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Sep 9, 2025 | clinicaltrials |
| NCT05862272 | A Phase 3B Study to Evaluate Bone Mineral Density With Long-Term Use of Relugolix Combination Tablet in Women With Uterine Fibroids or Endometriosis | recruiting | Phase 3 | 1,000 | Sumitomo Pharma Switzerland GmbHINDUSTRY | 1 | Aug 6, 2025 | clinicaltrials |
| NCT05056402 | An Immuno-bridging Study of a Nonavalent HPV Vaccine (E.Coli) in Healthy Population Aged 9-17 vs Aged 18-26 Years Old | active not recruiting | Phase 3 | 1,382 | Xiamen UniversityOTHER | 1 | Jul 22, 2025 | clinicaltrials |
| NCT06156514 | Evaluation of Concomitant Chemo-radiotherapy With Cisplatine vs Gemcitabin in Locally Advanced Cervicouterine Cancer(MICHELE) | recruiting | Phase 3 | 140 | National Institute of CancerologíaOTHER_GOV | 1 | May 28, 2025 | clinicaltrials |
| NCT03201861 | Addition of Cisplatin to Adjuvant Chemotherapy for Early Stage Breast Cancer in High-Risk Women | recruiting | Phase 3 | 762 | RenJi HospitalOTHER | 1 | May 16, 2025 | clinicaltrials |
| NCT06459687 | Phase III Study of Socazolimab as First-Line Treatment in Persistent, Recurrent, or Metastatic Cervical Cancer | recruiting | Phase 3 | 440 | Lee's Pharmaceutical LimitedINDUSTRY | 1 | May 14, 2025 | clinicaltrials |
| NCT06641635 | Moderated Hypofractionated Online Adaptive Radiotherapy in Cervical Cancer | recruiting | Phase 3 | 440 | Peking Union Medical College HospitalOTHER | 1 | Mar 18, 2025 | clinicaltrials |
| NCT06870565 | Comparative Study of Adjuvant Therapy for Postoperative Cervical Gastric-type Adenocarcinoma | not yet recruiting | Phase 3 | 238 | Women's Hospital School Of Medicine Zhejiang UniversityOTHER | 0 | Mar 17, 2025 | clinicaltrials |
| NCT06123884 | BAT1308 Combined with Platinum-Based Chemotherapy± Bevacizumab for PDL1-Positive (CPS ≥1) Cervical Cancer | recruiting | Phase 2 / Phase 3 | 526 | Bio-Thera SolutionsINDUSTRY | 1 | Feb 10, 2025 | clinicaltrials |
| NCT06584032 | Study of Fruquintinib Plus Sintilimab for Treatment of Advanced Endometrial Cancer | recruiting | Phase 3 | 412 | HutchmedINDUSTRY | 1 | Jan 7, 2025 | clinicaltrials |
| NCT06755515 | A Phase Ⅱ/Ⅲ Study of Rulonilimab Plus Chemotherapy± Bevacizumab for the First-Line Treatment of Persistent, Recurrent or Metastatic Cervical Cancer | enrolling by invitation | Phase 2 / Phase 3 | 510 | Shandong New Time Pharmaceutical Co., LTDINDUSTRY | 1 | Jan 1, 2025 | clinicaltrials |
| NCT01566240 | Induction Chemotherapy Plus Chemoradiation as First Line Treatment for Locally Advanced Cervical Cancer(INTERLACE) | active not recruiting | Phase 3 | 500 | University College, LondonOTHER | 5 | Dec 5, 2024 | clinicaltrials |
| NCT06692166 | A Study to Evaluate 9MW2821 Versus Treatment of Physician's Choice for Subjects With Recurrent or Metastatic Cervical Cancer | recruiting | Phase 3 | 420 | Mabwell (Shanghai) Bioscience Co., Ltd.INDUSTRY | 1 | Nov 22, 2024 | clinicaltrials |
| NCT03948789 | Phase III Study of MR-Guided Focused Ultrasound Surgery for the Treatment of Uterine Fibroids Compared to Myomectomy | active not recruiting | Phase 3 | 127 | Krankenhaus NordwestOTHER | 1 | Nov 13, 2024 | clinicaltrials |
| NCT04723875 | Postoperative Adjuvant Chemotherapy in Early-stage Cervical Cancer That Not Meet Criteria of Adjuvant Therapeutic According to NCCN Guideline | active not recruiting | Phase 3 | 306 | Huazhong University of Science and TechnologyOTHER | 1 | Nov 1, 2024 | clinicaltrials |
| NCT06288373 | Neoadjuvant Chemoimmunotherapy Versus Concurrent Chemoradiotherapy for LACC | recruiting | Phase 2 / Phase 3 | 440 | Tongji HospitalOTHER | 1 | Oct 30, 2024 | clinicaltrials |
| NCT05235516 | A Study of AK104/Placebo Combined With Chemoradiotherapy For The Treatment of Locally Advanced Cervical Cancer(AK104-305) | active not recruiting | Phase 3 | 636 | AkesoINDUSTRY | 1 | Aug 13, 2024 | clinicaltrials |
| NCT05764044 | Adjuvant Chemotherapy in cfHPV-DNA Plasma Positive Patients: A Biomarker In Locally Advanced Cervical Cancer(AddChemo) | recruiting | Phase 3 | 365 | Hospital do CoracaoOTHER | 1 | Jul 30, 2024 | clinicaltrials |
| NCT06509724 | Comparison of Conventional and Hypofractionated IMRT in High-Risk Cervical Cancer Post-Radical Hysterectomy(POHIM-P3) | recruiting | Phase 3 | 248 | Samsung Medical CenterOTHER | 1 | Jul 26, 2024 | clinicaltrials |
| NCT06475599 | Anlotinib Hydrochloride Capsules Combined With TQB2450 in the Treatment of Endometrial Cancer | not yet recruiting | Phase 3 | 420 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Jun 27, 2024 | clinicaltrials |
| NCT03755739 | Trans-Artery/Intra-Tumor Infusion of Checkpoint Inhibitors Plus Chemodrug for Immunotherapy of Advanced Solid Tumors | recruiting | Phase 2 / Phase 3 | 200 | Second Affiliated Hospital of Guangzhou Medical UniversityOTHER | 1 | Jun 25, 2024 | clinicaltrials |
| NCT04422366 | Evaluate the Efficacy, Immunogenicity and Safety of 9-valent HPV Recombinant Vaccine in Chinese Healthy Females | recruiting | Phase 3 | 8,000 | Shanghai Bovax Biotechnology Co., Ltd.INDUSTRY | 1 | Jun 7, 2024 | clinicaltrials |
| NCT05797831 | Study of Navtemadlin as Maintenance Therapy in TP53WT Advanced or Recurrent Endometrial Cancer | recruiting | Phase 2 / Phase 3 | 268 | Kartos Therapeutics, Inc.INDUSTRY | 17 | May 2, 2024 | clinicaltrials |
| NCT05027776 | Immunogenicity and Safety of Quadrivalent HPV Vaccine in Healthy Chinese Female Subjects Aged 9 to 19 Years | recruiting | Phase 3 | 1,348 | Shanghai Bovax Biotechnology Co., Ltd.INDUSTRY | 1 | Apr 17, 2024 | clinicaltrials |
| NCT01820858 | The Efficacy and Safety of the Postoperative Adjuvant Treatment in Patients With High-risk Stage I Endometrial Carcinoma(EC-01) | active not recruiting | Phase 3 | 300 | Ding MaOTHER | 1 | Apr 2, 2024 | clinicaltrials |
| NCT06333821 | A Study of Nimotuzumab Plus Concurrent Chemoradiotherapy Sequential Maintenance Treatment for Cervical Carcinoma | not yet recruiting | Phase 3 | 460 | Biotech Pharmaceutical Co., Ltd.OTHER | 0 | Mar 27, 2024 | clinicaltrials |
| NCT05173272 | Induction Chemotherapy Combined With Immunotherapy Followed by Concurrent Chemoradiation in Advanced Cervical Cancer | recruiting | Phase 3 | 286 | Sichuan Cancer Hospital and Research InstituteOTHER | 1 | Dec 27, 2023 | clinicaltrials |
| NCT03469674 | PORTEC-4a: Molecular Profile-based Versus Standard Adjuvant Radiotherapy in Endometrial Cancer(PORTEC-4a) | active not recruiting | Phase 3 | 550 | Leiden University Medical CenterOTHER | 8 | Oct 11, 2023 | clinicaltrials |
| NCT04989647 | Intermediate Risk Cervical Cancer: Radical Surgery +/- Adjuvant Radiotherapy(CERVANTES) | recruiting | Phase 3 | 514 | The Central and Eastern European Gynecologic Oncology GroupOTHER | 1 | Sep 7, 2023 | clinicaltrials |
| NCT02221999 | Weekly Paclitaxel and Cisplatin to Treat Hormone Receptor Positive and Triple Negative Breast Cancer Patients(SHPD002) | active not recruiting | Phase 2 / Phase 3 | 250 | RenJi HospitalOTHER | 1 | Aug 29, 2023 | clinicaltrials |
| NCT05735145 | Concurrent Chemoradiotherapy Combined With Adjuvant Chemotherapy Treated Advanced Cervical Cancer | recruiting | Phase 3 | 108 | Fourth Affiliated Hospital of Guangxi Medical UniversityOTHER | 1 | Feb 21, 2023 | clinicaltrials |
| NCT05524389 | Study of Early Stage Endometrial Cancer Based on Molecular Classification and Traditional Risk Stratification to Guide Adjuvant Radiotherapy Decisions | not yet recruiting | Phase 3 | 624 | Peking Union Medical College HospitalOTHER | 0 | Nov 23, 2022 | clinicaltrials |
Data updated 23 days agoSource updated Apr 15, 2026source: clinicaltrials